Management of Benign Prostatic Hyperplasia in Primary Care
Alpha-blockers should be initiated as first-line medical therapy for symptomatic BPH, with 5-alpha reductase inhibitors (5-ARIs) added for patients with prostates >30cc, PSA >1.5 ng/mL, or palpable enlargement on digital rectal exam. 1
Initial Evaluation Requirements
Obtain these specific elements at the first visit:
- International Prostate Symptom Score (IPSS) to quantify severity and bother
- Medical history focusing on medication review (anticholinergics, decongestants that worsen symptoms)
- Physical examination including digital rectal exam to estimate prostate size
- Urinalysis to exclude infection or hematuria 1
Counsel patients immediately on behavioral modifications (fluid timing, caffeine/alcohol reduction, double voiding) alongside pharmacotherapy options 1.
Medical Management Algorithm
First-Line Therapy: Alpha-Blockers
Start with an alpha-blocker (tamsulosin, alfuzosin, silodosin, or doxazosin) for all symptomatic patients regardless of prostate size 1, 2. These target the dynamic component of obstruction by relaxing smooth muscle in the prostate and bladder neck.
Exception: If the patient has comorbid erectile dysfunction, tadalafil 5mg daily is an acceptable alternative first-line option 1.
When to Add 5-Alpha Reductase Inhibitors
Add a 5-ARI (finasteride or dutasteride) to the alpha-blocker only when any of these criteria are met:
- Prostate volume >30cc on imaging
- PSA >1.5 ng/mL
- Palpable prostatic enlargement on DRE 1
This combination therapy prevents disease progression and reduces risk of acute urinary retention, as demonstrated in the MTOPS and CombAT trials 1. The 5-ARI targets the static component by reducing prostate volume over 6-12 months.
Critical caveat: 5-ARIs lower PSA by approximately 50% after 6 months. Always double the PSA value when screening for prostate cancer in patients on 5-ARIs. Failure to adjust PSA values leads to delayed cancer diagnosis and worse oncologic outcomes 1.
Storage Symptoms (Urgency, Frequency, Nocturia)
For patients with predominant storage symptoms despite alpha-blocker therapy:
- Add an anticholinergic (oxybutynin, tolterodine) to the alpha-blocker for moderate-to-severe storage LUTS 1
- Alternatively, add a beta-3 agonist (mirabegron) to the alpha-blocker 1
Both options address overactive bladder symptoms that may coexist with or result from bladder outlet obstruction.
Tadalafil Considerations
Tadalafil 5mg daily can be used as monotherapy or with alpha-blockers, but do not combine tadalafil with alpha-blockers expecting additive benefit—it offers no advantage over either agent alone 1. Use tadalafil primarily when erectile dysfunction coexists with LUTS.
Follow-Up Protocol
Reassess at 4-12 weeks after initiating any therapy (unless adverse effects require earlier evaluation). At follow-up:
- Repeat IPSS to quantify response (≥3-point improvement is clinically meaningful)
- Consider post-void residual and uroflowmetry if response is suboptimal 1
When to Refer to Urology
Refer immediately for surgical evaluation if any of these develop:
- Refractory urinary retention
- Recurrent urinary tract infections attributable to BPH
- Bladder stones
- Chronic kidney disease from obstruction
- Gross hematuria refractory to medical management
- Inadequate symptom improvement despite optimal medical therapy 2
Common Pitfalls
Alpha-blocker side effects: Warn about orthostatic hypotension, dizziness, and retrograde ejaculation. Tamsulosin and silodosin have lower cardiovascular effects than doxazosin.
5-ARI side effects: Sexual dysfunction (decreased libido, erectile dysfunction) occurs in 5-10% of patients. Gynecomastia is rare but bothersome.
PSA monitoring failure: The most dangerous error is not doubling PSA values in 5-ARI users, leading to missed or delayed prostate cancer diagnoses with worse cancer-specific mortality 1.
Anticholinergic use: Screen for contraindications (narrow-angle glaucoma, urinary retention risk). Monitor post-void residuals as anticholinergics can precipitate retention in severe obstruction.